tisagenlecleucel
novartis
['tisagenlecleucel', 'lymsm', 'lymphoma', 'elara', 'follicular']
the phase 2 elara trial indicated continued durable responses when patients with relapsed/refractory follicular lymphoma were treated with tisagenlecleucel. #lymsm #ash22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.